Disclaimer: The content provided in this newsletter is for informational purposes only and does not constitute investment advice. We are not registered investment advisors, and nothing in this newsletter should be construed as a recommendation to buy or sell any securities. Always do your own research and consult with a licensed financial professional before making any investment decisions.
Several months back, we introduced C3 as a “shadow play” on Palantir (PLTR), while flagging the renewal risk with Baker Hughes early on. Now that this quarter’s earnings are out, we’ve gained further thoughts on the company’s direction moving forward.


